Inventor · disambiguated record
Erica Pyles
Also filed as: PYLES ERICA
24 granted patents·12 pending applications·81 citations·filing 2019–2025
96Inventor score
Files withREGENERON PHARMA36
Top patents by PatentIndex Score
36 records- 0198US11459373B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2021·Granted Oct 4, 2022·8 cites·16 claims
- 0298US11459374B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2022·Granted Oct 4, 2022·13 cites·26 claims
- 0398US11299532B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2021·Granted Apr 12, 2022·8 cites·22 claims
- 0498US11174283B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2021·Granted Nov 16, 2021·13 cites·12 claims
- 0598US11053280B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2020·Granted Jul 6, 2021·19 cites·11 claims
- 0697US12049489B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2023·Granted Jul 30, 2024·2 cites·30 claims
- 0797US11649273B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2022·Granted May 16, 2023·2 cites·28 claims
- 0897US11407813B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2021·Granted Aug 9, 2022·3 cites·20 claims
- 0996US12180272B2Antigen binding molecule formatsREGENERON PHARMA·Filed 2022·Granted Dec 31, 2024·2 cites·11 claims
- 1096US11708407B2Antigen binding molecule formatsREGENERON PHARMA·Filed 2022·Granted Jul 25, 2023·2 cites·26 claims
- 1194US12202883B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2024·Granted Jan 21, 2025·0 cites·12 claims
- 1294US11505594B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2022·Granted Nov 22, 2022·1 cites·27 claims
- 1394US11180540B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2020·Granted Nov 23, 2021·2 cites·28 claims
- 1494US2025197474A1Anti-vegf protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1592US12391753B2Antigen binding molecule formatsREGENERON PHARMA·Filed 2024·Granted Aug 19, 2025·0 cites·22 claims
- 1691US12215148B2Antigen binding molecule formatsREGENERON PHARMA·Filed 2020·Granted Feb 4, 2025·2 cites·25 claims
- 1791US11286290B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2021·Granted Mar 29, 2022·1 cites·30 claims
- 1891US2025333492A1Antigen binding molecule formatsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1990US12331109B2Antigen binding molecule formatsREGENERON PHARMA·Filed 2024·Granted Jun 17, 2025·0 cites·23 claims
- 2090US12077570B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2023·Granted Sep 3, 2024·0 cites·30 claims
- 2188US11098112B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2020·Granted Aug 24, 2021·1 cites·26 claims
- 2287US12054533B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2022·Granted Aug 6, 2024·0 cites·18 claims
- 2387US11965020B2Antigen binding molecule formatsREGENERON PHARMA·Filed 2023·Granted Apr 23, 2024·0 cites·24 claims
- 2487US2025289883A1Novel antigen binding molecule formatsREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2586US11754569B2Methods for characterizing protein complexesREGENERON PHARMA·Filed 2019·Granted Sep 12, 2023·2 cites·20 claims
- 2678US12474349B2Methods for characterizing protein complexesREGENERON PHARMA·Filed 2023·Granted Nov 18, 2025·0 cites·18 claims
- 2778US2024167984A1Methods for detecting and determining protein structures and stability in fluids, including biological fluidsREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2878US2024168018A1Methods for detecting and evaluating viruses and virus-like particlesREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2978US2025206803A1Methods of characterizing and purifying vegf receptor fusion proteinREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 3072US2023417701A1Ce-western applications for antibody developmentREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3167US11782023B2Ce-western applications for antibody developmentREGENERON PHARMA·Filed 2019·Granted Oct 10, 2023·0 cites·18 claims
- 3267US2024385188A1Labeling and anti-drug antibody assays for aav vectorsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 3367US2025035532A1Methodology to characterize empty-full ratio in crude aav samplesREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 3458US2023296559A1Methods and systems for analyzing polypeptide variantsREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3550US2020393455A1Methods for identifying and quantitating host cell proteinREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 3649US2020369720A1Characterization of domain-specific charge variants of antibodiesREGENERON PHARMA·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Erica Pyles files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →